ARTICLE | Clinical News
Exicure reports Phase Ib data for psoriasis candidate
May 11, 2018 6:32 PM UTC
Exicure Inc. (Skokie, Ill.) said AST-005 did not significantly decrease echo lucent band thickness compared with placebo in a German Phase Ib trial in 25 patients with chronic plaque psoriasis. The company said echo lucent band thickness is a "key indicator" of efficacy in psoriasis patients. No serious adverse events were reported.
In 2016, Exicure granted Purdue Pharma L.P. (Stamford, Conn.) exclusive options to multiple programs, including AST-005 (see BioCentury, Dec. 15, 2016)...
BCIQ Target Profiles